Numerous preclinical studies have demonstrated the inhibitory function of T cell
immunoglobulin mucin domain-containing protein 3 (Tim-3) on T cells as an inhibitory …

T cell immunoglobulin and mucin domain-3 (TIM-3), a crucial immune checkpoint following
PD1 and CTLA4, is widely found in several immune cells. Nonetheless, its performance in …

Pediatric high-grade gliomas (pHGGs), including hemispheric pHGGs and diffuse midline
gliomas (DMGs), harbor mutually exclusive tumor location-specific histone mutations. Using …

The success of immunotherapy for cancer treatment is limited by the presence of an
immunosuppressive tumor microenvironment (TME); Therefore, identifying novel targets to …

Despite being the leading cause of cancer-related childhood mortality, pediatric gliomas
have been relatively understudied, and the repurposing of immunotherapies has not been …

This Review explores how tumor-associated regulatory cells (Tregs) affect cancer
immunotherapy. It shows how Tregs play a role in keeping the immune system in check, how …

Diffuse midline gliomas (DMGs) pose treatment challenges due to their location within the
brainstem and invasive nature. Although classical immune checkpoint inhibitors have …

Diffuse intrinsic pontine glioma (DIPG) remains intractable to conventional treatments. While
targeted therapy and immuno-oncology advances offer hope, few strategies show promising …

Cancer immunotherapy, leveraging antibodies, excels in targeting efficacy but faces hurdles
in tissue penetration, oral delivery, and prolonged half-life, with costly production and risk of …

Diffuse intrinsic pontine glioma (DIPG) is a childhood malignancy of the brainstem with a
dismal prognosis. Despite recent advances in its understanding at the molecular level, the …